The strong beat and raised guidance confirm the Health Care Benefits margin recovery thesis is on track. Monitor the Health Services and Pharmacy Consumer Wellness segments for continued pressure from pharmacy client price improvements and reimbursement headwinds. The raised FY guidance provides a clear catalyst for upward EPS revisions.
Price Chart
Executive Summary
CVS Health reported strong Q1 2026 results with Adjusted EPS of $2.57, significantly beating the $2.21 consensus estimate, and raised full-year 2026 guidance across all key metrics. Total revenues grew 6.2% YoY to $100.4B, driven by a sharp improvement in the Health Care Benefits segment (MBR improved 270 bps to 84.6%). The company raised its FY2026 Adjusted EPS guidance range to $7.30-$7.50 from $7.00-$7.20, signaling confidence in margin recovery despite cautious commentary on macro headwinds.
Key Financial Metrics
Key Facts
- Q1 2026 Adjusted EPS of $2.57 vs consensus $2.21 (beat by +16.3%)
- Q1 2026 GAAP diluted EPS of $2.30 vs $1.41 YoY
- Total revenues $100.4B, up 6.2% YoY from $94.6B
- Health Care Benefits segment MBR improved to 84.6% from 87.3% YoY (-270 bps)
- Health Care Benefits adjusted operating income surged 52.6% to $3.04B
- FY2026 Adjusted EPS guidance raised to $7.30-$7.50 from $7.00-$7.20
- FY2026 GAAP diluted EPS guidance raised to $6.24-$6.44 from $5.94-$6.14
- FY2026 cash flow from operations guidance raised to at least $9.5B from at least $9.0B
- Operating income increased 38.7% to $4.68B, driven by absence of prior-year litigation charges and segment improvement
- Health Services segment adjusted operating income declined 7.1% YoY to $1.49B
- Pharmacy Consumer Wellness segment adjusted operating income declined 8.8% YoY to $1.20B
Financial Impact
Q1 Adjusted EPS beat consensus by $0.36 (+16.3%); full-year guidance raised by $0.30 at midpoint
Risk Factors
- Health Services segment adjusted operating income declining 7.1% YoY signals ongoing PBM pricing pressure
- Pharmacy Consumer Wellness adjusted operating income down 8.8% YoY due to reimbursement pressure and seasonal illness weakness
- Management noted 'cautious view' on macro headwinds and elevated cost trends for remainder of 2026
- Medical membership declined ~600K sequentially due to individual exchange exit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000064803-26-000051 |
| Document: cvs-20260506.htm | 0000064803-26-000051 |
| Document: 0000064803-26-000051-index-headers.html | 0000064803-26-000051 |
| Document: 0000064803-26-000051-index.html | 0000064803-26-000051 |
| Document: 0000064803-26-000051.txt | 0000064803-26-000051 |
| 8-K Data (Synthetic) | 0000064803-26-000051 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $99.12 $97.23 | ▼ −1.91% | ▼ −1.31% | $85.20 (−14.04%) |
Jul 10, 2026 11w ago | Press Release | $104.15 $95.46 | ▼ −8.35% | ▼ −10.77% | $85.20 (−18.19%) |
Jun 29, 2026 13w ago | Court Ruling | $103.58 $107.74 | ▲ +4.02% | ▲ +4.30% | $85.20 (−17.74%) |
May 22, 2026 18w ago | S-3ASR | $90.55 $101.57 | ▲ +12.17% | ▲ +14.44% | $85.20 (−5.91%) |
May 19, 2026 19w ago | Court Ruling | $93.11 $99.16 | ▲ +6.50% | ▲ +6.54% | $85.20 (−8.49%) |
May 15, 2026 20w ago | Court Ruling | $95.88 $100.68 | ▲ +5.01% | ▲ +2.89% | $85.20 (−11.14%) |
May 6, 2026 21w ago | 8-K | $86.76 $91.37 | ▲ +5.32% | ▲ +2.54% | $85.20 (−1.79%) |
May 4, 2026 21w ago | Court Ruling | $82.01 $89.50 | ▲ +9.13% | ▲ +3.34% | $85.20 (+3.89%) |
Apr 29, 2026 22w ago | Court Ruling | $83.84 $92.97 | ▲ +10.89% | ▲ +4.85% | $85.20 (+1.62%) |
Apr 14, 2026 24w ago | Court Ruling | $77.60 $92.22 | ▼ −18.85% | ▼ −12.55% | $85.20 (−9.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access